We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · December 12, 2020

ASH 2020: Fixed-Duration Ibrutinib-Venetoclax Is Promising First-Line Option for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In patients who achieve undetectable minimal residual disease, 12 cycles of combination therapy may be sufficient to achieve remission

PracticeUpdate Editorial Team


Further Reading